BioNTech CEO Ugur Sahin sells 76,500 shares

BioNTech SE (BNTX) reported that Chief Executive Officer Ugur Sahin sold a total of 76,500 Ordinary Shares in open-market transactions pursuant to a Rule 10b5-1 trading plan established on June 3, 2026.

Rhea-AI Filing Summary

BioNTech SE (BNTX) reported that Chief Executive Officer Ugur Sahin sold a total of 76,500 Ordinary Shares in open-market transactions pursuant to a Rule 10b5-1 trading plan established on June 3, 2026. The sales occurred on September 3 and September 4, 2026 at prices just above $102 and $103 per share.

Insider Trade Summary 10b5-1

Net Seller: 76,500 shares

Net Sell 2 txns

Insider Sahin Ugur

Role Chief Executive Officer

Sold 76,500 shs ($7.89M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	31,500	$103.5182	$3.26M
Sale	Ordinary Shares	45,000	$102.8496	$4.63M

Holdings After Transaction: Ordinary Shares — 781,709 shares (Direct)

Key Figures

Shares sold on September 3, 2026: 45,000 Ordinary Shares Average sale price on September 3, 2026: $102.8496 per share Shares sold on September 4, 2026: 31,500 Ordinary Shares +3 more

6 metrics

Shares sold on September 3, 2026 45,000 Ordinary Shares Open-market sale by Ugur Sahin

Average sale price on September 3, 2026 $102.8496 per share Open-market sale of 45,000 Ordinary Shares by Ugur Sahin

Shares sold on September 4, 2026 31,500 Ordinary Shares Open-market sale by Ugur Sahin

Average sale price on September 4, 2026 $103.5182 per share Open-market sale of 31,500 Ordinary Shares by Ugur Sahin

Total shares sold in reported transactions 76,500 Ordinary Shares Combined sales on September 3 and 4, 2026 by Ugur Sahin

Rule 10b5-1 trading plan adoption date June 3, 2026 Plan under which the reported sales were effected

Key Terms

Rule 10b5-1 trading plan

1 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

What insider transaction did BioNTech (BNTX) disclose for Ugur Sahin?

BioNTech disclosed that Chief Executive Officer Ugur Sahin sold 76,500 Ordinary Shares of BioNTech SE in open-market transactions on September 3 and September 4, 2026, carried out under a pre-established Rule 10b5-1 trading plan adopted on June 3, 2026.

How many BioNTech (BNTX) shares did Ugur Sahin sell on each date and at what prices?

Ugur Sahin sold 45,000 Ordinary Shares of BioNTech SE on September 3, 2026 at an average price of $102.8496 per share, and 31,500 Ordinary Shares on September 4, 2026 at an average price of $103.5182 per share.

What is the total number of BioNTech (BNTX) shares sold by Ugur Sahin in this Form 4?

In this set of reported transactions, Ugur Sahin sold a combined total of 76,500 Ordinary Shares of BioNTech SE, consisting of 45,000 shares sold on September 3, 2026 and 31,500 shares sold on September 4, 2026.

Were Ugur Sahin’s BioNTech (BNTX) share sales made under a Rule 10b5-1 trading plan?

Yes. The reported sales of BioNTech SE Ordinary Shares by Ugur Sahin were effected pursuant to a Rule 10b5-1 trading plan that he established on June 3, 2026, indicating the transactions were pre-arranged according to that plan.

Is this BioNTech (BNTX) insider transaction a purchase or a sale of shares?

The reported insider activity consists of sales of BioNTech SE Ordinary Shares by Chief Executive Officer Ugur Sahin. Two open-market sale transactions are reported, with no purchases or derivative exercises included in this disclosure.

What role does Ugur Sahin hold at BioNTech (BNTX) in connection with these transactions?

Ugur Sahin is identified as the Chief Executive Officer of BioNTech SE and a ten percent owner. The Form 4 reports his sales of BioNTech Ordinary Shares carried out under his Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:11 PM Accepted by SEC EDGAR 09/08/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sahin Ugur

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/03/2026		S		45,000	D	$102.8496	813,209	D
Ordinary Shares	09/04/2026		S		31,500	D	$103.5182	781,709	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.

	/s/ Humza Bokhari, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)